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Accepted August 6, 1990 Abstract-Effects of FRG-8701, a new histamine H2-receptor antagonist , on gastric acid secretion, necrotizing agents-induced gastric lesions and acute gastric or duodenal ulcer in rats were studied.
In lumen-perfused rats, intravenous in jection of FRG-8701 reduced gastric acid secretion, and its antisecretory effect was almost equipotent to that of famotidine but the duration of action was sub stantially longer.
In pylorus-ligated rats, the antisecretory effect of intraduodenal FRG-8701 administration was about 7 times more potent than that of cimetidine. FRG-8701 effectively inhibited macroscopic gastric hemorrhagic lesions induced by various kinds of necrotizing agents.
Intraperitoneal injection was effective in preventing the lesions as well as oral treatment.
The oral ED50 values for these lesions ranged from 1.1 to 9.4 mg/kg.
On the other hand, famotidine failed to reduce these lesions, and the cytoprotective effect of cimetidine was observed only in high doses compared with the doses for antisecretory activity. In addition, the cytoprotective effect of FRG-8701 was not affected by the treatment of indo methacin or N-ethylmaleimide. FRG-8701 showed antiulcer activity against stress and indomethacin gastric ulcer and mepirizole duodenal ulcer. Its antiulcer effect was 5-15 times more potent than that of cimetidine.
These results indicate that FRG-8701 is a new antiulcer drug that exerts a potent cytoprotective effect in addition to its gastric antisecretory activity.
Since Black et al. (1) first defined the H2 receptor and characterized a number of H2 antagonists, various kinds of H2-antagonists have been developed and used clinically. The introduction of H2-antagonists has revolu tionized the treatment of peptic ulcers with its potent inhibition of gastric acid secretion. It has been, however, demonstrated that the recurrence ratio of peptic ulcer is relatively high after healing by long-term H2-antagonist therapy. In the clinical stage, patients are treated with H2-antagonist in combination with defensive factors potentiating-agents to prevent the ulcer relapse. On the other hand, interest has grown in discovering therapeutic agents that prevent ulcer formation or relapse by increasing defensive factors in the gut. The property of a drug that protects the gastric mucosa against necrotizing agents such as acid and ethanol has been coined cytoprotec tion (2) . Although these cytoprotective mechanisms are unknown, the protective effect by an agent is mainly considered to be due to the increase of gastric mucosal defensive integrity.
From this point of view, in our search for an H2-receptor antagonist that exerts both anti secretory and cytoprotective activities, we have found
phenoxy] propyl] -2 (furfuryl sulfinyl)acetamide (Fig. 1) . In present study, the effects of FRG-8701 on gastric acid secretion, necrotizing agents-induced gastric lesions and ulceration in rat stomach and duodenum were mainly investigated and com pared with those of reference H2-receptor antagonists.
Materials and Methods
In vitro studies
Male Hartley guinea pigs (Sankyo Labo Service Co.) weighing 250-350 g were used in the following in vitro studies.
1.1 Isolated atria: The hearts were excised from animals and right atria were dissected carefully. Atria were suspended in Krebs Henseleit (KH) solution maintained at 32°C and aerated with 95%02 and 5% CO2. The tissue was attached with an initial load of 1 g to an isometric transducer (Nihon Kohden, TD-112S) and allowed to stabilize for 60 min before histamine application.
The control chronotropic response to 10-5 M histamine was first established. The histamine response was repeated 10 min after the tissue was incubated with various concentrations of FRG-8701 or reference H2-antagonist. Data were expressed as a percentage of the control histamine response.
1.2 Isolated ileum: A 2 to 3-cm piece of ileum was removed from the animal and sus pended in KH solution maintained at 32°C and aerated with 95%02 and 5% CO2. The tissue was attached to an isotonic transducer (Nihon Kohden, TB-651T) with an initial load of 1 g and allowed to stabilize for 30-60 min.
A control concentration-response curve to histamine or acetylcholine was established in a cumulative fashion until a consistent maxi mal response was obtained. After 10 min in cubation with 10-5 M FRG-8701, the hista mine or acetylcholine response curve was repeated. Data were expressed as a percen tage of the maximum histamine or acetylcho line response without FRG-8701.
In vivo studies
Male Sprague Dawley (SD) rats (Charles River, Inc., Japan) weighing 180-200 g were fasted overnight before experiments in the following in vivo studies, but in the case of mepirizole-induced duodenal ulcer, rats were deprived of food and water 24 hr after mepiri zole administration.
2.1 Acid secretion in lumen-perfused rat: Animals were anesthetized with urethane (1.4 g/kg, Lm.) and surgically prepared as de scribed by Ghosh and Schild (3). The stomach of the rat was perfused with warm saline at the rats of 1 ml/min, and acid in the perfusate was estimated by titration to pH 7.0 every 15 min. The animals were infused continuously via caudal veins with histamine 2HCI (4 mg/kg/hr), and test compounds were injected intravenously 1 hr after initiation of histamine infusion. Data were expressed as a percentage of the value of acid secretion 1 hr after the initiation of histamine infusion.
2.2 Acid secretion in pylorus-ligated rat: While under ether anesthesia, the abdomen was opened and the pylorus was ligated. Test compounds were given intraduodenally at the time of ligation. Four hours after pylorus ligation, rats were sacrificed and the gastric contents were centrifuged and analyzed for volume and acidity. Acid concentration was determined by titration to pH 7.0. Total acid output was calculated as the volume times the acid concentration.
2.3 Necrotizing agents-induced gastric lesions: Gastric mucosal lesions were pro duced using various kinds of necrotizing agents: absolute ethanol, 0.6 N HCI, 1% ammonia (1% N H3), 0.4 N HCI + 50% ethanol (HCI ethanol), and 0.15 M taurocholic sodium + 0.4 N HCI, according to the method of Robert et al. (2) . Each drug or vehicle of 5% arabic gum solution was given to individual rats orally 30 min prior to oral treatment of 1 ml of necrotizing agent. One hour after necrotiz ing agent treatment, the animals were sacri ficed. The stomach was removed and in flated by injecting 10 ml of 2% formalin. Subsequently, the stomach was incised along the curvature and examined for macroscopic hemorrhagic damages under a dissecting microscope (x10). The area of each lesion (mm2) was measured, and the sum of the area was regarded as the lesion index. In addition, FRG-8701 was given intraperitoneally before HCI-ethanol treatment. In some cases, in domethacin, a cyclooxygenase inhibitor (10 mg/kg), or N-ethylmaleimide, an SH blocker (5 mg/kg) was given subcutaneously 2.5 hr or 10 min before FRG-8701 treatment.
2.4 Acute gastric or duodenal ulcer: Stress ulcer was induced by immersing rats in water (23'C) for 6 hr according to the method of Takagi and Okabe (4) . Indomethacin ulcer was produced by subcutaneous injection of indomethacin at 20 mg/kg, and the rats were sacrificed 6 hr after the treatment. Duodenal ulcer was induced by administration of me pirizole at the dose of 200 mg/kg, and the rats were sacrificed 24 hr later (5, 6) .
Each drug or vehicle was given 30 min before the ulcerogenic treatment; and in the case of mepirizole duodenal ulcer, drugs were given twice, 30 min before mepirizole ad ministration and 9 hr later.
After formalin fixation, the area (mm2) of the lesion in each animal was summed under a dissecting microscope (x10) and used as the ulcer index. 
Results
In vitro studies: Positive chronotropic re sponse to histamine at 10-5 M was dose dependently inhibited by FRG-8701 famoti dine or cimetidine; and the IC50 values of FRG-8701, famotidine and cimetidine were 3.3, 3.0 and 108.6 (X10-7 M), respectively. The inhibitory potency of FRG-8701 was almost the same as that of famotidine and ap proximately 33 times greater than that of cimetidine (Table 1) .
FRG-8701 at 10-5 M did not cause any significant displacement of the histamine or acetylcholine concentration-response curve in the ileal preparation (Fig. 2) .
Gastric acid secretion: In anesthetized rats with perfused stomach, the control acid output response at 1 hr after the initiation of (Fig. 3) . The reference H2 antagonists also inhibited acid output in a dose-dependent manner. As shown in Fig. 3 , the antisecretory potency of intravenous FRG 8701 appeared to be the same as that of famotidine, and the recovery from the anti secretory activity of FRG-8701 was appre ciably slower than the recoveries from those of cimetidine and famotidine.
In the pylorus-ligated (4 hr) rats, each drug, given intraduodenally, dose-dependently inhibited the total acid output; and the ED50 values for 50% reduction of the total acid output are listed in Table 2 .
Cytoprotective studies: FRG-8701 at 10 or 30 mg/kg, given orally or 1ntraperitonea Ily, significantly prevented the formation of the gastric mucosal lesions induced by 0.4 N HCI + 50% ethanol (HCI•ethanol) (Fig. 4) . Other necrotizing agents-induced gastric lesions were also inhibited by treatment of FRG-8701 ( (Fig. 5) .
Studies of antiulcer activity: FRG-8701, given orally, dose-dependently prevented the development of gastric lesions induced by stress (restraint and water immersion) and indomethacin (Table 3) . Duodenal ulcer induced by mepirizole was also inhibited with FRG-8701. The ED50 values of FRG-8701 for each ulcer model ranged from 1.7 to 6.9 mg/ kg. Famotidine and cimetidine also dose dependently reduced the lesions, and the ED50 values are listed in Table 3 . 
Discussion
The present studies demonstrated that FRG-8701 is a potent antisecretory agent in rats.
In histamine-stimulated and lumen perfused rats, the intravenous potency of FRG-8701 was greater than that of cimetidine and appeared to be the same as that of famotidine from Fig. 3 . In addition, persistent inhibition of acid secretion was observed 3-4 hr after administration of FRG-8701, while the antisecretory effect of famotidine and that of cimetidine disappeared during the same period. These results indicate that FRG-8701 has relatively long-lasting antisecretory ef fects in comparison with famotidine and cimetidine.
In pylorus-ligated rats, the in traduodenal antisecretory effect of FRG-8701 was about 7 times more potent than that of cimetidine and 4 times less potent than that of famotidine. The present studies showed that the inhibitory potency of FRG-8701 on the chronotropic responses of isolated atria to 10-5 M histamine was 33 times greater than that of cimetidine and almost equal to that of famotidine. The selectivity of FRG-8701 for H2-receptors was indicated by its lack of in hibitory activity against the histamine or acetylcholine response in isolated guinea pig ileum under conditions where the maximal H2-inhibition in the atria was produced. Since the relative antisecretory potencies among the H2-antagonists are nearly identical to their relative H2-blocking activities in the isolated atria (8, 9) , the H2-blocking activity of FRG-8701 in the atria may explain why its antisecretory effects are equivalent to that of famotidine in intravenously administered rats with lumen-perfusion.
FRG-8701 effectively prevented formation of the gastric hemorrhagic mucosal lesions induced by various necrotizing agents in the dose range exhibiting the antisecretory effect in pylorus-ligated rats. Although the cyto protective action of cimetidine remains con troversial (10) (11) (12) (13) , the reduction of lesions was observed by cimetidine treatment, but its cytoprotective doses were apparently dif ferent from its antisecretory doses. It seems likely that FRG-8701 exerts such a cytopro tective action mainly through a systemic action because both orally and intraperi toneally administered FRG-8701 were ef fective, indicating that the cytoprotection of FRG-8701
was not induced through the mechanisms of a mild irritant. It is important that the cytoprotective action is not caused by the antisecretory action. In the present study, a sufficient amount of exogenous acid (0.6 N HCI, 0.4 N HCI + 50% ethanol, 0.4 N HCI + taurocholic sodium) was used; and famoti dine, unlike FRG-8701, failed to prevent formation of the gastric mucosal lesion even at high doses. These results indicate that FRG 8701 elicits the cytoprotective action on the gastric mucosa by some mechanism other than inhibition of acid secretion or histamine H2-receptor antagonism.
Szabo and Trier (14) proposed that gastric cytoprotection might be mediated through at least two different mechanisms, one involves prostaglandins and the other involves sulfhy dryl-containing substances of the mucosa. Pretreatment with N-ethylmaleimide, by itself, significantly aggravated the HCI ethanol lesions and these results were consistent with those of Takeuchi et al. (15) . They suggested that the enhancement of vascular permeability by N-ethylmaleimide may account for the aggravation of ethanol-induced gastric lesions. On the other hand, in spite of suf ficient amounts of indomethacin to decrease endogenous prostaglandins, the severity of mucosal lesions in response to HCI•ethanol was hardly affected. However, there was significant protection by FRG-8701 regard less of the treatment by indomethacin or N ethylmaleimide. These results suggest that endogenous prostaglandins and sulfhydryls may not be involved in the mechanism of gastric cytoprotection afforded by FRG-8701. Although the mechanisms of cytoprotection by FRG-8701 are unknown, an increasing ac tion on gastric mucosal blood flow was ob served by intravenous administration of FRG 8701 in our preliminary studies (data not shown). This increasing action on gastric mucosal blood flow may be partially re sponsible for its cytoprotective effect. Further studies are in progress to explain it.
FRG-8701 was also very effective in pre venting the formation of experimental gastric and duodenal ulcers. Its antiulcer activity was 5-15 times more potent than that of cimeti dine and almost identical to that of famotidine in the case of stress ulcer. The ulcer formation elicited by stress, indomethacin and mepiri zole is noticeably inhibited by bilateral vagotomy or antacid treatment (4, 6, 16) . It is, therefore, postulated that gastric acid plays an important role in ulceration by these treatments. In fact, the prevention of ulcer formation is ascribed to the suppression of acid secretion based on the results that its ef fective doses in the inhibition of indomethacin or mepirizole ulcer are sufficient to decrease the acid secretion. On the contrary, cytopro tective activity may participate in the inhibi tory effect of FRG-8701 on stress ulcer in addition to the antisecretory effect since FRG 8701 prevented the ulcer at doses less than the ED50 for reduction in the acid output in pylorus-ligated rats.
Histamine H2-receptor antagonists can be categorized into two classes. The first class is agents that can be considered to be relatively short-acting in vivo like cimetidine and ranitidine. The second class is composed of compounds that have potent and long lasting antisecretory activity. FRG-8701 belongs in this second class. Recent clinical studies suggested that adequate ulcer healing can be achieved solely by controlling noc turnal gastric acid secretion, thus precluding the need for maintenance of a full 24-hr antisecretory effect (17) . Thus, the second class compounds could replace cimetidine and ranitidine because they can be delivered as a convenient once daily dosage. However, the occurrence of gastric hyperplasia after long-term treatment with certain long-acting antisecretory agents such as loxidine (18) and omeprazole (19) has raised doubts about the safety and desirability of prolonged gastric achlorhydria. From this point of view, it would seem that FRG-8701 with a moderate dura tion of antisecretory activity, e.g., greater than cimetidine and ranitidine but less than loxidine and omeprazole, would be a beneficial and desirable agent. In the light of ulcer relapse, it was reported thatgastric lesions to ulcerogenic stimuli were aggravated after H2-antagonist treatment (20, 21) , and suggested that the in creased mucosal vulnerability associated with H2-antagonists might be responsible for the high ulcer recurrence ratio after H2-antagonist therapy (21) . However, further studies are needed to explain the high relapse ratio. As a result of potent cytoprotection, FRG-8701 seems to possess reinforcement effects on gastric mucosal defensive integrity in addi tion to its antisecretory effect. As such, this agent is expected to be useful for the treat ment of peptic ulcers in humans.
